Details for Patent: 10,869,869

Which drugs does patent 10,869,869 protect, and when does it expire?

Patent 10,869,869 protects TAFINLAR and MEKINIST and is included in two NDAs.

Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in twenty countries.

Summary for Patent: 10,869,869

Title:	Method of adjuvant cancer treatment
Abstract:	The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Inventor(s):	Laquerre; Sylvie (King of Prussia, PA), Lebowitz; Peter F. (Research Triangle Park, NC)
Assignee:	Novartis AG (Basel, CH)
Application Number:	16/664,978
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,869,869

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No					Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes					Y

International Family Members for US Patent 10,869,869

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013313050
Australia	2016244279
Brazil	112015004578
Canada	2882437
China	104582706
China	107308164